All In Biotech

Drug Trial Radar · NCT03611868

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Aug 29, 2018

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.

Conditions

  • Unresectable or Metastatic Melanoma or Advanced Solid Tumors
  • Melanoma
  • Uveal Melanoma
  • P53 Mutation
  • MDM2 Gene Mutation
  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Malignant Peripheral Nerve Sheath Tumors (MPNST)

Interventions

  • Phase 1b: APG-115+pembrolizumabDrug

    dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle. Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated DoseTime frame: 21 days
  2. Recommended Phase II DoseTime frame: 21 days
  3. Overall Response RateTime frame: up to 12 months

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona

  • Highlands Oncology

    Rogers, Arkansas

  • UCLA Hematology & Oncology Clinic

    Los Angeles, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Children's National Research Institute

    Washington D.C., District of Columbia

  • Sarah Cannon/FCSRI

    Fort Myers, Florida

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Penn State Hershey Medical Center Cancer Institute

    Hershey, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Next Oncology

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Metro South Hospital and Health Services via Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.